Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma

ConclusionBenefit/risk profile of nivolumab in Eastern-Spanish real-world population with mRCC after tyrosine-kinase inhibitors was consistent with prior real-life studies reported as well as pivotal study.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research